CLINICAL_TRIALS
trial_result
· 2022-05-19
Clinical Trial Update: A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive [Phase 2]
Summary
Phase IIb trial update for BPI-7711 capsules in non-small cell lung cancer patients with T790M mutation (Phase 2, completed).
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Beta Pharma Shanghai | Conditions: NSCLC | Phase 2 | Status: COMPLETED